^
    Back
    Association details:
    Biomarker:CD20 positive
    Cancer:Childhood B Acute Lymphoblastic Leukemia
    Drug:Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    12/02/2021
    Excerpt:
    RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of...Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) (1.1)...Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy.
    Secondary therapy:
    Chemotherapy